This HIV-1 Integrase Genotype test is designed to detect mutations associated with resistance to raltegravir dolutegravir or elvitegravir, the only FDA-approved HIV integrase strand transfer inhibitors (INSTIs) currently available. These drugs represent a class of antiretrovirals that inhibit the catalytic activity of integrase and thereby prevent formation of the HIV provirus required for viral propagation.
Integrase resistance testing is recommended for patients experiencing virologic failure while taking these integrase inhibitors. It can also be considered as a supplement to standard baseline genotypic resistance testing if transmitted resistance to either drug is suspected.
Baseline and/or when failing therapy
Reference Range Contact Laboratory
Sample Required EDTA whole blood
Sample Volume 10mL
Turnaround Time 14 days
Must have quantifiable HIV-1 viral load. Sequencing previously performed externally now done in-house